Lysis Buffer for High Yield Enzymatic Shearing news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Advancing the Diagnosis and Treatment of Ovarian Cancer
insights from industryDr. Marcos Quintela VasquezResearch and Development Innovation OfficerRBGO Research Group
In this interview, News-Medical talks to Dr. Marcos Quintela Vasquez about the work he is conducting regarding the diagnosis and treatment of ovarian cancer in partnership with CEAT and Porvair Sciences.
Please tell us about CEAT, your project aims and how the group of partners was assembled?
The Cluster for Epigenomic and Antibody Drug Conjugate (ADC) Therapeutics (CEAT) is a Swansea University-led partnership between key multi-national players Glaxo Smith Kline (GSK), Cytiva and Bruker, together with UK-based partners Porvair Sciences Ltd, Axis Bio, and BiVictriX. The CEAT project, jointly funded by the Welsh European Funding Office and collaborating partners, is designed to enable partners to deliver advances in epigenetic and ADC-based ovarian cancer therapeutics.